Enterome
A clinical stage biopharmaceutical company developing developing breakthrough immunomodulatory drugs for the treatment of cancer and inflammatory diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | €8.7m Valuation: €232m | Late VC | |
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (25 %) | 742 % | 200 % | (81 %) | (73 %) | 26 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (549 %) | (19 %) | 48 % | (168 %) | (806 %) | (715 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (534 %) | (66 %) | 45 % | (119 %) | (683 %) | (621 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Enterome is a clinical-stage company that is developing innovative cancer treatments. The company operates in the healthcare sector, specifically in the field of oncology. Its primary clients are patients suffering from various types of cancer, including recurrent glioblastoma and Non-Hodgkin lymphoma.
The company's business model revolves around the development and commercialization of its proprietary OncoMimics™ technology. This technology stimulates a patient's own immune system to fight cancer, overcoming the body's natural tolerance to self-antigens. In simpler terms, it trains the body's immune cells to recognize and attack cancer cells.
Enterome's most advanced programs, EO2401 and EO2463, are currently in Phase 2 clinical trials. These trials have shown promising results in terms of efficacy and safety in over 180 patients. The company's research and development platform has the potential to deliver multiple candidates for cancer treatment, with a rapid progression from laboratory research to patient treatment.
In addition to its cancer treatments, Enterome has also established a partnership with Nestlé Health Science to develop treatments for inflammatory diseases and food allergies. This diversification of its product portfolio allows Enterome to tap into different segments of the healthcare market.
Enterome generates revenue through the development and commercialization of its treatments. The company also stands to earn income from its partnership with Nestlé Health Science.
Keywords: Enterome, cancer treatments, OncoMimics™ technology, immune-oncology, clinical trials, EO2401, EO2463, Nestlé Health Science partnership, inflammatory diseases, food allergies.